에 대한 최신 뉴스 Veracyte (NASDAQ:VCYT) 주식

Veracyte

Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.

Equities

News

Markets

Tech

ETFs

ADPT

ARKG

ARKK

CDNA

PLTR

VCYT

월요일(13일) 캐시 우드가 이끄는 아크 인베스트는 팔란티어 테크놀로지스(NASDAQ:PLTR), 템퍼스 AI(NASDAQ:TEM), 케어Dx (NASDAQ:CDNA), 베라사이트(NASDAQ:VCYT), 어댑티브 바이오테크놀로지스 (NASDAQ:ADPT) 등 5개의 주요 기업에서 중요한 거래를 진행했다.

캐시 우드의 아크 인베스트, 팔란티어 주가 하락 속 추가 매도

Biotech

Health Care

BEAM

CRSP

NTLA

RXRX

TWST

아크 인베스트의 CEO인 캐시 우드는 인공지능, 유전자 염기서열(시퀀싱) 분석, 유전자 편집 기술의 교차점에서 전례 없는 잠재력을 발견하고 바이오 분야에 투자를 강화하고 있다.

캐시 우드, 바이오 분야에서 4천억 달러 기회 전망

Mid Cap

Movers

ADMA

Core Scientific, Inc. - Class A Common Stock

CORZ

LUMN

UPST

다음은 지난주 큰 폭의 상승세를 보인 7개의 중형주 주식이다. 이 주식들은 여러분의 포트폴리오에 있나요? 루멘 테크놀로지스(NYSE:LUMN)의 주가는 회사가 2분기 매출 결과를 보고한 후 113.82% 급등했다. 여러 분석가가 주식의 목표 가격을 상향 조정했다.

루멘 테크 및 업스타트는 지난주 최고 성과를 보여준 7개 중형주 중 일부 (8월 4일-8월 10일)

Veracyte Inc

Piper Sandler has upgraded Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>), a molecular diagnostic testing and precision medicine company.
Analyst David Westenberg says Myriad Genetics&#8217; management team set an overly aggressive LRP. Since then, two events—the loss of a private payer&#8217;s reimbursement on Genesight and an NCCN guideline language change—have led to an over 50% decline in the stock in the last six months.
Westenberg writes that Myriad Genetics risks missing this year&#8217;s guidance and might need to set 2026 expectations below the LRP.
&#8220;We think Myriad&#8217;s biggest remaining potential downside is expectations set by a previous CEO, and we believe the stock will find a bottom around this ~1x revenue range,&#8221; Piper Sandler writes.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/02/43953008/myriad-genetics-faces-cost-restructuring-as-unitedhealthcare-ends-genesight-coverage-appoints-new-ceo" rel="noreferrer noopener">Myriad Genetics Faces Cost Restructuring As UnitedHealthcare Ends GeneSight Coverage, Appoints New CEO</a>
BMO Capital writes Myriad Genetics has faced challenges in the urology and prostate testing market, losing some ground to Deciphera Pharmaceuticals and Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) in recent years.
However, the company has taken steps to stand out, including a new partnership with PATHOMIQ to integrate AI with molecular testing. Myriad Genetics plans to launch a test for patients after radical prostatectomy and radiation treatment later this year or early next year. This test will be offered alongside Prolaris as a combined option.
Piper Sandler writes that the stock has stabilized, allowing new CEO Sam Raha to reshape the business, set clear strategies and align expectations. The analyst has upgraded the stock from Neutral to Overweight, with a price target of $12.50, <a href="https://www.benzinga.com/quote/MYGN/analyst-ratings" target="_blank" rel="noreferrer noopener">up from $11.50</a>.
Price Action: MYGN stock is up 2.44% at $10.50 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/03/44283318/gilead-presents-new-hiv-treatment-and-cure-research-data" target="_blank" rel="noreferrer noopener">Gilead Presents New HIV Treatment And Cure Research Data</a></li>
</ul>

Analyst Color

Upgrades

Analyst Ratings

General

MYGN

Analyst Sees Bottom For Myriad Genetics Stock, Issues Upgrade

5 analysts have expressed a variety of opinions on Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Veracyte, revealing an average target of $46.6, a high estimate of $51.00, and a low estimate of $37.00. Witnessing a positive shift, the current average has risen by 4.02% from the previous average price target of $44.80.
<img src="https://www.benzinga.com/files/images/story/2025/1740510024_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Veracyte. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lu Li</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$49.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Subbu Nambi</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$51.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$51.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$37.00</td>
<td>$38.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Veracyte. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Veracyte compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Veracyte's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Veracyte's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/VCYT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Veracyte analyst ratings.</a>
<h2>Get to Know Veracyte Better</h2>
Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others.
<h3>A Deep Dive into Veracyte's Financials</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Veracyte displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 28.58%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Veracyte's net margin is impressive, surpassing industry averages. With a net margin of 13.08%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Veracyte's ROE excels beyond industry benchmarks, reaching 1.31%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Veracyte's ROA stands out, surpassing industry averages. With an impressive ROA of 1.21%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Veracyte's debt-to-equity ratio is below the industry average. With a ratio of 0.02, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Veracyte Through 5 Analysts

On Monday, Veracyte Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) reported adjusted earnings of 36 cents. That&#8217;s up from 21 cents a year ago, beating the <a href="https://www.benzinga.com/pressreleases/25/02/b43925680/veracyte-announces-fourth-quarter-and-full-year-2024-financial-results" target="_blank" rel="noreferrer noopener">consensus of 11 cents</a>.
The global diagnostic company reported sales of $118.6 million, up from $98.2 million a year ago. It beat the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus of $116.77 million</a>.
Testing revenue was $112.2 million, an increase of 24% year over year, driven by the strong performance of Decipher and Afirma tests. Total volume increased by 22% to 41,271 tests and testing volume by 25% to 39,107 tests.
Veracyte is evaluating its ownership and operations of its Marseille, France-based subsidiary, Veracyte SAS. The company's activities include its immune-oncology biopharma business, contract development and manufacturing, and support for its IVD development and manufacturing.&nbsp;
Veracyte recently notified Veracyte SAS that, as its sole shareholder, it is considering no longer funding the French entity. Accordingly, Veracyte SAS will engage with its works council over the next few months, as required by French law.
Seeking external buyer(s) for a potential divestiture of all or part of the French entity's activities is an option that is actively being explored.
William Blair analyst Andrew Brackmann writes, &#8220;While this adds a bit of uncertainty about the total company revenue and margins, we think walking away (or selling) could be a long-term positive.&#8221;
The analyst says the French subsidiary earns about $4 million in revenue each quarter but has $7 million in fixed costs, leading to a $5 million operating loss. Selling the unit or filing for bankruptcy could help Veracyte reduce costs.
Guidance: The company expects 2025 testing revenue of $470 million to $480 million, or 12% to 15% year-over-year growth.
The guidance implies testing revenue growth of 14% to 16%, adjusted for the impact of the paused Envisia test.
Given the number of variables impacting its Marseille, France operations, the company is not providing total revenue guidance now. It expects to provide its total revenue outlook for 2025 once there is more clarity on the timing and impact of the process underway.
The company also expects its adjusted EBITDA margin to be approximately 21.6% in 2025, compared to 20.6% in 2024.
Price Action: VCYT stock is down 2.90% at $38.23 during the premarket session on last check Tuesday.

Earnings

Guidance

Trading Ideas

Diagnostic Company Veracyte Weighs Sale For French Subsidiary, Analyst Says 'Walking Away' Is A Long-Term Positive

UBS analyst Lu Li maintains Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) with a Buy and raises the price target from $46 to $49.

Price Target

UBS Maintains Buy on Veracyte, Raises Price Target to $49

Guggenheim analyst Subbu Nambi reiterates Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) with a Buy and maintains $45 price target.

Reiteration

Guggenheim Reiterates Buy on Veracyte, Maintains $45 Price Target

Needham analyst Mike Matson reiterates Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) with a Buy and maintains $51 price target.

Needham Reiterates Buy on Veracyte, Maintains $51 Price Target

WIIM

Veracyte shares are trading lower. The company reported Q4 financial results.

Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) reported quarterly earnings of $0.36 per share which beat the analyst consensus estimate of $0.11 by 227.27 percent. This is a 620 percent increase over earnings of $0.05 per share from the same period last year. The company reported quarterly sales of $118.600 million which beat the analyst consensus estimate of $116.765 million by 1.57 percent. This is a 20.78 percent increase over sales of $98.199 million the same period last year.

Earnings Beats

Veracyte Q4 2024 Adj. EPS $0.36 Beats $0.11 Estimate, Sales $118.600M Beat $116.765M Estimate

Veracyte Sees FY25 Testing Revenue $470M-$480M.

<h3>Companies Reporting Before The Bell</h3>
• Kosmos Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KOS#NYSE">KOS</a>) is expected to report quarterly earnings at $0.00 per share on revenue of $416.02 million. 
• Lincoln Educational Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINC#NASDAQ">LINC</a>) is estimated to report quarterly earnings at $0.29 per share on revenue of $110.85 million. 
• Summit Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) is projected to report earnings for its fourth quarter. 
• Clear Channel Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCO#NYSE">CCO</a>) is estimated to report quarterly earnings at $0.03 per share on revenue of $645.84 million. 
• BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) is expected to report quarterly loss at $0.06 per share on revenue of $127.72 million. 
• Domino's Pizza (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>) is expected to report quarterly earnings at $4.95 per share on revenue of $1.48 billion. 
• Gran Tierra Energy (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GTE#AMEX">GTE</a>) is projected to report earnings for its fourth quarter. 
• Westlake Chemical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLKP#NYSE">WLKP</a>) is likely to report quarterly earnings at $0.37 per share on revenue of $1.08 billion. 
• Westlake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLK#NYSE">WLK</a>) is estimated to report quarterly earnings at $1.18 per share on revenue of $2.96 billion. 
• Owens-Corning (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OC#NYSE">OC</a>) is likely to report quarterly earnings at $2.90 per share on revenue of $2.77 billion. 
• Fresh Del Monte Produce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDP#NYSE">FDP</a>) is expected to report quarterly earnings at $0.37 per share on revenue of $1.03 billion. 
• Kaspi.kz (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KSPI#NASDAQ">KSPI</a>) is estimated to report quarterly earnings at $3.35 per share on revenue of $1.52 billion. 
• Freightos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGO#NASDAQ">CRGO</a>) is estimated to report quarterly loss at $0.09 per share on revenue of $6.46 million. 
• Azul (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZUL#NYSE">AZUL</a>) is projected to report quarterly earnings at $0.10 per share on revenue of $1.01 billion. 
<h3>Companies Reporting After The Bell</h3>
• DMC Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOOM#NASDAQ">BOOM</a>) is likely to report quarterly loss at $0.29 per share on revenue of $140.50 million. 
• Ultra Clean Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCTT#NASDAQ">UCTT</a>) is estimated to report quarterly earnings at $0.44 per share on revenue of $559.19 million. 
• Clean Energy Fuels (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLNE#NASDAQ">CLNE</a>) is estimated to report quarterly loss at $0.01 per share on revenue of $99.87 million. 
• Goosehead Insurance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSHD#NASDAQ">GSHD</a>) is likely to report quarterly earnings at $0.40 per share on revenue of $78.20 million. 
• Trex Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TREX#NYSE">TREX</a>) is likely to report quarterly earnings at $0.04 per share on revenue of $159.89 million. 
• Atlas Energy Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AESI#NYSE">AESI</a>) is likely to report quarterly earnings at $0.18 per share on revenue of $281.61 million. 
• Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) is projected to report quarterly earnings at $0.21 per share on revenue of $469.68 million. 
• Beyond (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYON#NYSE">BYON</a>) is likely to report quarterly loss at $0.75 per share on revenue of $331.06 million. 
• Coterra Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRA#NYSE">CTRA</a>) is projected to report quarterly earnings at $0.42 per share on revenue of $1.39 billion. 
• Faro Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FARO#NASDAQ">FARO</a>) is estimated to report quarterly earnings at $0.40 per share on revenue of $91.03 million. 
• Riot Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>) is likely to report quarterly loss at $0.27 per share on revenue of $130.25 million. 
• BWX Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWXT#NYSE">BWXT</a>) is likely to report quarterly earnings at $0.81 per share on revenue of $720.47 million. 
• SBA Comms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBAC#NASDAQ">SBAC</a>) is projected to report quarterly earnings at $2.22 per share on revenue of $684.39 million. 
• ONEOK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKE#NYSE">OKE</a>) is estimated to report quarterly earnings at $1.55 per share on revenue of $6.77 billion. 
• Chegg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHGG#NYSE">CHGG</a>) is projected to report quarterly earnings at $0.18 per share on revenue of $142.03 million. 
• Artivion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AORT#NYSE">AORT</a>) is projected to report quarterly earnings at $0.04 per share on revenue of $101.15 million. 
• EverQuote (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVER#NASDAQ">EVER</a>) is projected to report quarterly earnings at $0.39 per share on revenue of $133.83 million. 
• Cannae Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNNE#NYSE">CNNE</a>) is projected to report quarterly loss at $0.29 per share on revenue of $105.90 million. 
• Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) is estimated to report quarterly earnings at $0.26 per share on revenue of $116.68 million. 
• Primoris Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRIM#NYSE">PRIM</a>) is estimated to report quarterly earnings at $0.76 per share on revenue of $1.59 billion. 
• Realty Income (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/O#NYSE">O</a>) is estimated to report quarterly earnings at $1.06 per share on revenue of $1.35 billion. 
• Trip.com Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCOM#NASDAQ">TCOM</a>) is likely to report quarterly earnings at $0.54 per share on revenue of $1.69 billion. 
• HealthStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSTM#NASDAQ">HSTM</a>) is expected to report quarterly earnings at $0.14 per share on revenue of $73.55 million. 
• Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) is estimated to report quarterly earnings at $0.03 per share on revenue of $213.34 million. 
• Archrock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AROC#NYSE">AROC</a>) is likely to report quarterly earnings at $0.29 per share on revenue of $326.77 million. 
• Topgolf Callaway Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MODG#NYSE">MODG</a>) is likely to report quarterly loss at $0.19 per share on revenue of $885.10 million. 
• Haverty Furniture Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HVT#NYSE">HVT</a>) is likely to report quarterly earnings at $0.22 per share on revenue of $182.09 million. 
• JBT Marel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBTM#NYSE">JBTM</a>) is estimated to report quarterly earnings at $1.85 per share on revenue of $488.74 million. 
• ProAssurance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRA#NYSE">PRA</a>) is likely to report quarterly earnings at $0.19 per share on revenue of $274.56 million. 
• Inspirato (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPO#NASDAQ">ISPO</a>) is estimated to report quarterly loss at $1.09 per share on revenue of $58.34 million. 
• Quaker Houghton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KWR#NYSE">KWR</a>) is projected to report quarterly earnings at $1.61 per share on revenue of $441.87 million. 
• Apartment Inv &amp; Mgmt (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIV#NYSE">AIV</a>) is estimated to report quarterly loss at $0.12 per share on revenue of $53.10 million. 
• Navitas Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) is projected to report quarterly loss at $0.06 per share on revenue of $19.03 million. 
• Tempus AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>) is projected to report quarterly loss at $0.15 per share on revenue of $200.55 million. 
• Addus HomeCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>) is expected to report quarterly earnings at $1.35 per share on revenue of $278.36 million. 
• Helios Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLIO#NYSE">HLIO</a>) is estimated to report quarterly earnings at $0.36 per share on revenue of $175.99 million. 
• Ziff Davis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZD#NASDAQ">ZD</a>) is likely to report quarterly earnings at $2.63 per share on revenue of $424.40 million. 
• Agora (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/API#NASDAQ">API</a>) is estimated to report earnings for its fourth quarter. 
• Black Stone Minerals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSM#NYSE">BSM</a>) is expected to report quarterly earnings at $0.33 per share on revenue of $114.99 million. 
• LTC Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LTC#NYSE">LTC</a>) is likely to report quarterly earnings at $0.65 per share on revenue of $42.81 million. 
• Zoom Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) is projected to report quarterly earnings at $1.35 per share on revenue of $1.19 billion. 
• Douglas Dynamics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLOW#NYSE">PLOW</a>) is likely to report quarterly earnings at $0.31 per share on revenue of $155.23 million. 
• MediaAlpha (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAX#NYSE">MAX</a>) is expected to report quarterly earnings at $0.39 per share on revenue of $289.38 million. 
• SI-BONE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIBN#NASDAQ">SIBN</a>) is projected to report quarterly loss at $0.14 per share on revenue of $46.89 million. 
• Bridge Investment Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRDG#NYSE">BRDG</a>) is expected to report quarterly earnings at $0.17 per share on revenue of $83.69 million. 
• Tortoise Capital Series Trust Tortoise Power and Energy Infrastructure Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPZ#NYSE">TPZ</a>) is expected to report earnings for its fourth quarter. 
• Offerpad Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OPAD#NYSE">OPAD</a>) is likely to report quarterly loss at $0.48 per share on revenue of $174.58 million. 
• Helix Energy Solns Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLX#NYSE">HLX</a>) is likely to report quarterly earnings at $0.09 per share on revenue of $311.66 million. 
• Public Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSA#NYSE">PSA</a>) is projected to report quarterly earnings at $4.22 per share on revenue of $1.18 billion. 
• Clearway Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWEN#NYSE">CWEN</a>) is expected to report earnings for its fourth quarter. 
• V2X (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VVX#NYSE">VVX</a>) is projected to report quarterly earnings at $1.15 per share on revenue of $1.10 billion. 
• Veris Residential (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRE#NYSE">VRE</a>) is expected to report quarterly earnings at $0.12 per share on revenue of $66.81 million. 
• GFL Environmental (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFL#NYSE">GFL</a>) is projected to report quarterly earnings at $0.23 per share on revenue of $1.98 billion. 
• Summit Hotel Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INN#NYSE">INN</a>) is projected to report quarterly earnings at $0.19 per share on revenue of $171.47 million. 
• Civitas Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIVI#NYSE">CIVI</a>) is estimated to report quarterly earnings at $1.88 per share on revenue of $1.29 billion. 
• Cleveland-Cliffs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) is expected to report quarterly loss at $0.44 per share on revenue of $4.54 billion. 
• Netstreit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTST#NYSE">NTST</a>) is estimated to report quarterly earnings at $0.32 per share on revenue of $43.47 million. 
• KBR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBR#NYSE">KBR</a>) is estimated to report quarterly earnings at $0.82 per share on revenue of $2.00 billion. 
• Viper Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNOM#NASDAQ">VNOM</a>) is projected to report quarterly earnings at $0.42 per share on revenue of $220.06 million. 
• Diamondback Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>) is likely to report quarterly earnings at $3.58 per share on revenue of $3.51 billion. 
• Apple Hospitality REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APLE#NYSE">APLE</a>) is likely to report quarterly earnings at $0.31 per share on revenue of $324.82 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADUS

AESI

AORT

APLE

AROC

AZUL

BCRX

BOOM

BRDG

BWXT

BYON

CHGG

CIVI

CLNE

CNNE

CRGO

CTRA

CWEN

EVER

FANG

FARO

GSHD

Hims & Hers Health, Inc. Class A Common Stock

HIMS

HLIO

HSTM

ISPO

JBTM

KSPI

LINC

MODG

NTST

NVTS

OPAD

PLOW

PRIM

RIOT

SBAC

SIBN

SMMT

TCOM

TREX

UCTT

VNOM

WLKP

Earnings Scheduled For February 24, 2025

Here are two stocks with buy rank and strong momentum characteristics for investors to consider today, February 13th:
Veracyte, Inc. VCYT: This diagnostics company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 20.4% over the last 60 days.
<div class="chart_embed">
<h3>Veracyte, Inc. Price and Consensus</h3>
<a href="https://www.zacks.com/stock/chart/VCYT/price-consensus-chart?icid=chart-VCYT-price-consensus-chart"><img alt="Veracyte, Inc. Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/bc/1739432244.png" style="height:264px; width:571px" title="" /> </a>
<a href="https://www.zacks.com/stock/chart/VCYT/price-consensus-chart?icid=chart-VCYT-price-consensus-chart">Veracyte, Inc. price-consensus-chart</a> | <a href="https://www.zacks.com/stock/quote/VCYT?icid=chart-VCYT-price-consensus-chart">Veracyte, Inc. Quote</a>
</div>
Veracyte&#39;s shares gained 2.2% over the last three months compared with the S&amp;P 500&#39;s advance of 1%. The company possesses a&nbsp;<a href="https://www.zacks.com/style-scores-education/">Momentum Score</a>&nbsp; of A.
<div class="chart_embed">
<h3>Veracyte, Inc. Price</h3>
<a href="https://www.zacks.com/stock/chart/VCYT/fundamental/price?icid=chart-VCYT-fundamental/price"><img alt="Veracyte, Inc. Price" src="https://staticx-tuner.zacks.com/images/charts/3f/1739432367.png" style="height:250px; width:533px" title="" /> </a>
<a href="https://www.zacks.com/stock/chart/VCYT/fundamental/price?icid=chart-VCYT-fundamental/price">Veracyte, Inc. price</a> | <a href="https://www.zacks.com/stock/quote/VCYT?icid=chart-VCYT-fundamental/price">Veracyte, Inc. Quote</a>
</div>
Northern Trust Corporation NTRS: This wealth management company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 3.7% over the last 60 days.
<div class="chart_embed">
<h3>Northern Trust Corporation Price and Consensus</h3>
<a href="https://www.zacks.com/stock/chart/NTRS/price-consensus-chart?icid=chart-NTRS-price-consensus-chart"><img alt="Northern Trust Corporation Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/c1/1739432255.png" style="height:264px; width:572px" title="" /> </a>
<a href="https://www.zacks.com/stock/chart/NTRS/price-consensus-chart?icid=chart-NTRS-price-consensus-chart">Northern Trust Corporation price-consensus-chart</a> | <a href="https://www.zacks.com/stock/quote/NTRS?icid=chart-NTRS-price-consensus-chart">Northern Trust Corporation Quote</a>
</div>
Northern Trust&#39;s shares gained 3.05% over the past three months compared with the S&amp;P 500&#39;s advance of 1%. The company possesses a&nbsp;Momentum Score&nbsp;of A.
<div class="chart_embed">
<h3>Northern Trust Corporation Price</h3>
<a href="https://www.zacks.com/stock/chart/NTRS/fundamental/price?icid=chart-NTRS-fundamental/price"><img alt="Northern Trust Corporation Price" src="https://staticx-tuner.zacks.com/images/charts/0b/1739432385.png" style="height:252px; width:537px" title="" /> </a>
<a href="https://www.zacks.com/stock/chart/NTRS/fundamental/price?icid=chart-NTRS-fundamental/price">Northern Trust Corporation price</a> | <a href="https://www.zacks.com/stock/quote/NTRS?icid=chart-NTRS-fundamental/price">Northern Trust Corporation Quote</a>
</div>
&nbsp;
See the&nbsp;<a href="https://www.zacks.com/stocks/buy-list/?ADID=zp_1link&amp;ICID=zpi%20_1link">full list of top ranked stocks here</a>
&nbsp;
Learn more about the&nbsp;<a href="https://www.zacks.com/education/stock-scorecard/momentum-trading">Momentum score and how it is calculated here</a>.
&nbsp;
<h2>Zacks&#39; Research Chief Names &quot;Stock Most Likely to Double&quot;</h2>
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren&#39;t winners but this one could far surpass earlier Zacks&#39; Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
<a href="https://www.zacks.com/registration/ultimatetrader/welcome/eoffer/4e87?add=1590&amp;adid=SYND_BENZ_ZU_1S2DREPORT_ZACKS1RANKADDITIONS_267_02132025_2415045&amp;cid=CS-BENZ-FT-zacks_1_rank_additions|momentum_additions-2415045" style="font-weight:bold">Free: See Our Top Stock And 4 Runners Up</a>
&nbsp;
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. <a href="https://www.zacks.com/registration/pfp/?ALERT=RPT_7BST_LP194&amp;ADID=SYND_BENZ_7BEST_ZACKS1RANKADDITIONS_267_2415045&amp;cid=CS-BENZ-FT-zacks_1_rank_additions|momentum_additions-2415045" target="_blank">Click to get this free report</a>

&nbsp; 
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=NTRS&amp;ADID=SYND_BENZ_TCK_ZACKS1RANKADDITIONS_267_2415045_NTRS&amp;cid=CS-BENZ-FT-zacks_1_rank_additions|momentum_additions-2415045">Northern Trust Corporation (NASDAQ: </a><a class="ticker" href="https://www.benzinga.com/stock/ntrs#NASDAQ">NTRS</a>): Free Stock Analysis Report 
&nbsp; 
<a href="https://www.zacks.com/registration/pfp?ALERT=ZER_LINK&amp;t=VCYT&amp;ADID=SYND_BENZ_TCK_ZACKS1RANKADDITIONS_267_2415045_VCYT&amp;cid=CS-BENZ-FT-zacks_1_rank_additions|momentum_additions-2415045">Veracyte, Inc. (NASDAQ: </a><a class="ticker" href="https://www.benzinga.com/stock/vcyt#NASDAQ">VCYT</a>): Free Stock Analysis Report
<a href="https://www.zacks.com/commentary/2415045/best-momentum-stocks-to-buy-for-february-13th?cid=CS-BENZ-FT-zacks_1_rank_additions|momentum_additions-2415045">To read this article on Zacks.com click here.</a>
<a href="https://www.zacks.com/">Zacks Investment Research</a>

NTRS

Best Momentum Stocks To Buy For February 13th

7 analysts have expressed a variety of opinions on Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $41.14, a high estimate of $51.00, and a low estimate of $28.00. Observing a 9.91% increase, the current average has risen from the previous average price target of $37.43. 
<img src="https://www.benzinga.com/files/images/story/2025/1738155639_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A comprehensive examination of how financial experts perceive Veracyte is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$51.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$37.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$28.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$44.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$38.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Lu Li</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$46.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$44.00</td>
<td>$37.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Veracyte. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Veracyte compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Veracyte's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Veracyte's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/VCYT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Veracyte analyst ratings.</a>
<h2>Unveiling the Story Behind Veracyte</h2>
Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others.
<h3>Financial Insights: Veracyte</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Veracyte's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 28.58%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Veracyte's net margin is impressive, surpassing industry averages. With a net margin of 13.08%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Veracyte's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.31% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Veracyte's ROA excels beyond industry benchmarks, reaching 1.21%. This signifies efficient management of assets and strong financial health.
Debt Management: Veracyte's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.02.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Veracyte: Insights From 7 Analyst Reviews

Needham analyst Mike Matson maintains Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) with a Buy and raises the price target from $44 to $51.

Needham Maintains Buy on Veracyte, Raises Price Target to $51

On Monday, Cathie Wood-led Ark Invest made significant trades in five major companies: Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>), Tempus AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), CareDx Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>), Veracyte Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>), Adaptive Biotechnologies Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>).
The PLTR Trade
Ark Invest&#8217;s Ark Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>) fund sold 140,518 shares of Palantir. This move is significant, considering Ark Invest&#8217;s&nbsp;<a href="https://www.benzinga.com/25/01/42865484/cathie-woods-tuesday-double-dump-ark-invest-trims-both-palantir-and-bitcoin-etf-holdings">recent trend of offloading Palantir shares</a>.
The total value of this trade, based on the latest closing price of $64.98, is approximately $9.1 million.
This sale follows Ark&#8217;s disposal of shares worth roughly $15 million the previous week.
Palantir stock price has fallen more than 14% over the past month. In just the first two weeks of 2025, the stock has declined nearly 15%.
The TEM Trade
Ark Invest&#8217;s ARK Genomic Revolution ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>) and ARKK funds made substantial purchases of Tempus AI Inc. shares. The ARKG fund bought 98,691 shares, while the ARKK fund purchased a whopping 280,192 shares.
Given the latest closing price of $32.34, the total value of these trades amounts to approximately $12.2 million.
This move comes amid TEM&#8217;s 13.81% drop on Monday.
Other Key Trades:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Company</td>
<td>ETF</td>
<td>Transaction</td>
<td>No. Of Shares</td>
<td>Closing price</td>
<td>Approx. Value</td>
</tr>
<tr>
<td>Veracyte Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>)</td>
<td>ARK Genomic Revolution</td>
<td>Sale</td>
<td>37,358</td>
<td>$42.78</td>
<td>$1.6 million</td>
</tr>
<tr>
<td>Adaptive Biotechnologies Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>)</td>
<td>ARK Genomic Revolution</td>
<td>Sale</td>
<td>76,522</td>
<td>$6.46</td>
<td>$494,332</td>
</tr>
<tr>
<td>CareDx Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>)</td>
<td>ARK Genomic Revolution</td>
<td>Sale</td>
<td>65,550</td>
<td>$25.07</td>
<td>$1.6 million</td>
</tr>
</tbody>
</table>
</figure>
Closing price as of Jan. 13, 2025
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42931941/mark-zuckerberg-critiques-culturally-neutered-companies-advocates-for-masculine-energy-as-meta-cuts-dei-programs-post-joe-rogan-appearance">Mark Zuckerberg Critiques &#8216;Culturally Neutered&#8217; Companies, Advocates For &#8216;Masculine Energy&#8217; As Meta Cuts DEI Programs Post-Joe Rogan Appearance</a></li>
</ul>
Image via Benzinga YouTube and Unsplash
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/Rounak-Jain" target="_blank" rel="noreferrer noopener">Rounak Jain</a>

Cathie Wood's Ark Invest Trims Palantir Again As Peter Thiel Co-Founded Firm's Stock Tumbles Nearly 15% In 2025

9 analysts have expressed a variety of opinions on Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Veracyte, presenting an average target of $40.0, a high estimate of $46.00, and a low estimate of $28.00. Marking an increase of 10.68%, the current average surpasses the previous average price target of $36.14. 
<img src="https://www.benzinga.com/files/images/story/2024/1733414409_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Veracyte. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$37.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$28.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$44.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$38.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Lu Li</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$46.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$44.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Puneet Souda</td>
<td>Leerink Partners</td>
<td>Raises</td>
<td>Outperform</td>
<td>$40.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Lu Li</td>
<td>UBS</td>
<td>Announces</td>
<td>Buy</td>
<td>$43.00</td>
<td>-</td>
</tr>
<tr>
<td>Subbu Nambi</td>
<td>Guggenheim</td>
<td>Announces</td>
<td>Buy</td>
<td>$40.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Veracyte. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Veracyte compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Veracyte's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of Veracyte's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/VCYT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Veracyte analyst ratings.</a>
<h2>All You Need to Know About Veracyte</h2>
Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others.
<h3>Understanding the Numbers: Veracyte's Finances</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Veracyte's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 28.58%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 13.08%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 1.31%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Veracyte's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 1.21%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Veracyte's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.02.
<h2>What Are Analyst Ratings?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Navigating 9 Analyst Ratings For Veracyte

Goldman Sachs analyst Matthew Sykes downgrades Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) from Buy to Neutral and lowers the price target from $38 to $37.

Downgrades

Goldman Sachs Downgrades Veracyte to Neutral, Lowers Price Target to $37

Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies.
What Happened: Wood&#8217;s enthusiasm centers on what she describes as a transformative convergence of technologies that could revolutionize medical treatment and drug discovery. 
Speaking candidly about the sector, Wood highlighted the remarkable progress in genetic therapies, particularly in companies like Crispr Therapeutics AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>), Intellia Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>), and Beam Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>).
Her most striking example involves Crispr Therapeutics&#8217; recent breakthrough in sickle cell disease treatment. Wood noted, referencing how patients who previously required 12 to 20 annual blood transfusions might now be free from such interventions.
The strategy extends beyond treatment breakthroughs to drug development itself. Wood points to companies like Recursion Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) as leveraging artificial intelligence to dramatically reduce clinical trial failure rates and accelerate drug development timelines.
However, the market performance of these innovative companies tells a more nuanced story. Year-to-date, the stocks have experienced significant volatility: Crispr Therapeutics is down 25.36%, Intellia Therapeutics has dropped 52.21%, Beam Therapeutics declined 3.04%, and Recursion Pharmaceuticals fell 9.80%, according to <a href="https://www.benzinga.com/pro/">data from Benzinga Pro</a>.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Which market sector excites <a href="https://twitter.com/CathieDWood?ref_src=twsrc%5Etfw">@CathieDWood</a> the most and why? In <a href="https://twitter.com/hashtag/askARK?src=hash&amp;ref_src=twsrc%5Etfw">#askARK</a>, she shares her growing enthusiasm for the biologics space. Have more questions for Cathie? Share them in the comments. <a href="https://t.co/WjilZChce6">pic.twitter.com/WjilZChce6</a>
&mdash; ARK Invest (@ARKInvest) <a href="https://twitter.com/ARKInvest/status/1861431767506268404?ref_src=twsrc%5Etfw">November 26, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/general/entertainment/24/11/42205763/disney-reaches-43m-settlement-in-gender-pay-discrimination-lawsuit-women-can-expect-equitable-treatment-moving-forward">Disney Reaches $43M Settlement In Gender Pay Discrimination Lawsuit: &#8216;Women Can Expect Equitable Treatment&#8217; Moving Forward</a>
Why It Matters: ARK&#8217;s commitment to this sector is evident through its Genomic Revolution ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>), which manages net assets of $1.179 billion. The fund&#8217;s performance reflects the sector&#8217;s volatility, with annual returns ranging from a high of 180.50% in 2020 to a low of -53.94% in 2022.
The ETF&#8217;s current top holdings underscore Wood&#8217;s strategic focus on innovative biological technologies. Twist Bioscience Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>) leads the portfolio at 8.90%, followed by Crispr Therapeutics at 7.88% and Recursion Pharmaceuticals at 6.17%. Other significant investments include CareDx Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>), Veracyte Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>), and Adaptive Biotechnologies Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>), representing a diversified approach to genomic and biological innovation.
Wood&#8217;s vision suggests a potential $400 billion market opportunity in biologics over the next five years, driven by the unprecedented convergence of AI, sequencing technologies, and gene editing. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42202496/goldman-sachs-expects-major-selloffs-in-canadian-dollar-mexican-peso-says-trump-tariffs-threaten-usmca-agreement">Goldman Sachs Expects Major Selloffs In Canadian Dollar, Mexican Peso, Says Trump Tariffs Threaten USMCA Agreement</a></li>
</ul>
Image via Ark Invest
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?

Morgan Stanley analyst Tejas Savant maintains Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) with a Underweight and raises the price target from $26 to $28.

Morgan Stanley Maintains Underweight on Veracyte, Raises Price Target to $28

Scotiabank analyst Sung Ji Nam maintains Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) with a Sector Outperform and raises the price target from $40 to $44.

Scotiabank Maintains Sector Outperform on Veracyte, Raises Price Target to $44

Goldman Sachs analyst Matthew Sykes maintains Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) with a Buy and raises the price target from $34 to $38.

Goldman Sachs Maintains Buy on Veracyte, Raises Price Target to $38

Press Releases

Veracyte to Release Third Quarter 2024 Financial Results on November 6, 2024

Veracyte to Participate in Upcoming Investor Conferences

Veracyte Announces Third Quarter 2024 Financial Results

Veracyte's Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer Guidelines

Veracyte to Release Fourth Quarter and Full-Year 2024 Financial Results on February 24, 2025

New Study Shows Veracyte's Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder Cancer

Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests' Leadership in Urologic Cancers to Be Presented at the 2025 ASCO GU Symposium

New Data at ASCO GU Show Power of Veracyte's Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research

Veracyte Announces Fourth Quarter and Full Year 2024 Financial Results

ACADIA Pharmaceuticals Inc. - Common Stock

ACADIA Pharmaceuticals

Apogee Therapeutics

Apellis Pharmaceuticals, Inc. - Common Stock

Apellis Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. - Common Stock

Arrowhead Pharma

Beam Therapeutics

Biohaven

CG Oncology

Centessa Pharmaceuticals plc - American Depositary Shares

Centessa Pharmaceuticals

Catalyst Pharmaceuticals, Inc. - Common Stock

Catalyst Pharmaceuticals

Denali Therapeutics

Amicus Therapeutics

ImmunityBio

Immunovant

Disc Medicine

Janux Therapeutics

Kymera Therapeutics

Mirum Pharmaceuticals, Inc. - common stock

Mirum Pharmaceuticals

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake

Metsera

NewAmsterdam Pharma Company N.V. - Ordinary Shares

NewAmsterdam Pharma Co

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals

Rhythm Pharmaceuticals, Inc. - Common Stock

Rhythm Pharmaceuticals

Soleno Therapeutics

Twist Bioscience Corporation - Common Stock

Twist Bioscience

Vericel

Guggenheim

Needham

Goldman Sachs

Morgan Stanley

월요일(13일) 캐시 우드가 이끄는 아크 인베스트는 팔란티어 테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>), 템퍼스 AI(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), 케어Dx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>), 베라사이트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>), 어댑티브 바이오테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) 등 5개의 주요 기업에서 중요한 거래를 진행했다.
<h3>팔란티어 거래</h3>
아크 인베스트의 Ark Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)는 팔란티어 주식 140,518주를 매각했다. 이는 아크 인베스트가 최근에 팔란티어 주식을 처분하는 추세를 보인 것을 감안할 때 중요한 움직임이며, <a href="https://www.benzinga.com/25/01/42865484/cathie-woods-tuesday-double-dump-ark-invest-trims-both-palantir-and-bitcoin-etf-holdings">최근 경향</a>을 고려할 때 주목할 만하다.
최근 종가인 64.98달러를 기준으로 한 이번 거래의 총 가치는 약 910만 달러에 달한다. 이번 매각은 지난주 아크 인베스트가 약 1,500만 달러 상당의 팔란티어 주식을 처분한 데 이어 나타났다.
팔란티어 주가는 지난 한 달 동안 14.22% 하락했고, 올해 들어서는 14.77% 하락했다.
<h3>템퍼스 AI 거래</h3>
아크 인베스트의 ARK Genomic Revolution ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>)와 ARKK 펀드는 템퍼스 AI 주식 상당량을 매입했다. ARKG 펀드는 98,691주를 매입했고 ARKK 펀드는 무려 280,192주를 매입했다.
최근 종가인 32.34달러를 감안할 때, 이번 매입 거래의 총 가치는 약 1,220만 달러에 달한다. 이러한 움직임은 월요일에 템퍼스 AI 주가가 13.81% 하락한 가운데 나온 것이다.
<h3>기타 주요 거래</h3>
<figure class="wp-block-table">
<table style="overflow:auto; height: 90px; display: block;">
<tbody>
<tr>
<td>회사</td>
<td>ETF</td>
<td>거래</td>
<td>주식 수</td>
<td>종가</td>
<td>대략적 가치</td>
</tr>
<tr>
<td>베라사이트 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>)</td>
<td>ARK Genomic Revolution</td>
<td>매도</td>
<td>37,358</td>
<td>$42.78</td>
<td>$160만</td>
</tr>
<tr>
<td>어댑티브 바이오테크놀로지스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>)</td>
<td>ARK Genomic Revolution</td>
<td>매도</td>
<td>76,522</td>
<td>$6.46</td>
<td>$494,332</td>
</tr>
<tr>
<td>케어Dx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>)</td>
<td>ARK Genomic Revolution</td>
<td>매도</td>
<td>65,550</td>
<td>$25.07</td>
<td>$160만</td>
</tr>
</tbody>
</table>
</figure>
2025년 1월 13일 기준 종가
이미지 제공: Benzinga YouTube 및 Unsplash
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>를 사용하여 생성되었으며 <a href="https://www.benzinga.com/author/Rounak-Jain" target="_blank" rel="noreferrer noopener">Rounak Jain</a>이 편집했습니다.
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

아크 인베스트의 CEO인 캐시 우드는 인공지능, 유전자 염기서열(시퀀싱) 분석, 유전자 편집 기술의 교차점에서 전례 없는 잠재력을 발견하고 바이오 분야에 투자를 강화하고 있다.
무슨 일 있었나: 캐시 우드의 열정은 의료와 신약 개발에 혁명을 일으킬 수 있는 혁신적인 기술 융합에 집중되어 있다.
그는 이 분야에 대해 솔직하게 이야기하면서 특히 크리스퍼 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>), 인텔리아 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>), 빔 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) 같은 회사에서 유전자 치료의 괄목할 만한 발전이 이루어지고 있다고 강조했다.
가장 눈에 띄는 사례는 최근 크리스퍼 테라퓨틱스가 겸상 적혈구 질환 치료 분야에서 거둔 획기적인 성과다. 우드는 이전에는 연간 12~20회 수혈을 받아야 했던 환자들이 이제 그런 수혈을 받지 않아도 될 수 있게 되었다고 언급했다.
이러한 전략은 치료의 혁신을 넘어 신약 개발 자체로 확장횐다. 우드는 리커션 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>)와 같은 회사가 인공지능을 활용하여 임상시험 실패율을 획기적으로 줄이고 신약 개발 일정을 앞당기고 있다고 강조했다.
그러나 이러한 혁신적인 기업들의 시장 성과는 좀 더 복잡한 이야기를 담고 있다. 올해 들어 이들 주식은 상당한 변동성을 보였다. <a href="//www.benzinga.com/pro/"" target="_blank" rel="noopener">벤징가 프로 데이터</a>에 따르면 연초 대비 크리스퍼 테라퓨틱스는 25.36% 하락, 인텔리아 테라퓨틱스는 52.21% 하락, 빔 테라퓨틱스는 3.04% 하락, 리커션 제약은 9.80% 하락했다.
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Which market sector excites <a href="https://twitter.com/CathieDWood?ref_src=twsrc%5Etfw">@CathieDWood</a> the most and why? In <a href="https://twitter.com/hashtag/askARK?src=hash&amp;ref_src=twsrc%5Etfw">#askARK</a>, she shares her growing enthusiasm for the biologics space.
Have more questions for Cathie? Share them in the comments. <a href="https://t.co/WjilZChce6">pic.twitter.com/WjilZChce6</a>
&mdash; ARK Invest (@ARKInvest) <a href="https://twitter.com/ARKInvest/status/1861431767506268404?ref_src=twsrc%5Etfw">November 26, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
이 기사도 읽어보세요: <a href="https://kr.benzinga.com/news/usa/stocks/%EC%BA%90%EC%8B%9C-%EC%9A%B0%EB%93%9C%EC%9D%98-%EC%95%84%ED%81%AC-%EC%9D%B8%EB%B2%A0%EC%8A%A4%ED%8A%B8-%ED%85%8C%EC%8A%AC%EB%9D%BC-%EC%A3%BC%EC%8B%9D-1800%EB%A7%8C-%EB%8B%AC%EB%9F%AC-%EC%83%81/" target="_blank" rel="noopener">캐시 우드의 아크 인베스트, 테슬라 주식 1,800만 달러 상당 매각</a>
왜 중요한가: 바이오 분야에 대한 아크 인베스트의 노력은 11억 7,900만 달러의 순자산을 관리하는 Genomic Revolution ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>)를 통해 분명하게 드러난다. 이 펀드의 성과는 2020년 최고 180.50%에서 2022년 최저 -53.94%에 이르는 연간 수익률로 해당 섹터의 변동성을 반영하고 있다.
이 ETF의 현재 상위 보유 종목은 혁신적인 바이오 기술에 대한 캐시 우드의 전략적 초점을 강조한다. 트위스트 바이오사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>)가 8.90%의 비중으로 포트폴리오를 이끌고 있으며, 크리스퍼 테라퓨틱스가 7.88%, 리커션 파마슈티컬스가 6.17%로 그 뒤를 잇고 있다. 그 밖의 주요 투자 기업으로는 케어DX(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>), 베라사이트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>), 어댑티브 바이오테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) 등이 있으며, 이들은 게놈 및 생물학적 혁신에 대한 다양한 접근 방식을 대표한다.
캐시 우드는 AI, 시퀀싱 기술, 유전자 편집의 전례 없는 융합 덕분에 향후 5년 동안 바이오 분야에서 4,000억 달러의 시장 기회가 있을 것으로 전망한다.
이미지 출처: Ark Invest
면책 조항: 이 콘텐츠는 부분적으로 AI 도구의 도움을 받아 생성되었으며, Benzinga 편집자가 검토 후 게시했습니다.
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

다음은 지난주 큰 폭의 상승세를 보인 7개의 중형주 주식이다. 이 주식들은 여러분의 포트폴리오에 있나요?
<ol>
<li>루멘 테크놀로지스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>)의 주가는 회사가 <a href="https://www.benzinga.com//node/40204727" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">2분기 매출 결과</a>를 보고한 후 113.82% 급등했다. 여러 분석가가 주식의 <a href="https://www.benzinga.com//node/40221474" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">목표 가격</a>을 상향 조정했다.</li>
<li>업스타트 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>)가 <a href="https://www.benzinga.com//node/40227720" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">강한 2분기 실적을 발표</a>한 후 주가는 73.65% 급등했다. 많은 분석가들은 주식의 <a href="https://www.benzinga.com//node/40229270" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">목표 가격</a>을 상향 조정했다.</li>
<li>ADMA 바이오로직스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>)의 주가는 예상보다 나은 2분기 재무 결과를 보고하면서 지난주 52.58% 상승했다.</li>
<li>스위트그린(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SG#NYSE">SG</a>)이 <a href="https://www.benzinga.com//node/40284819" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">예상보다 나은 2분기 재무 실적</a>을 보고하고 강력한 FY24 수익 전망을 발표한 후 가 주가는 47.35% 상승했다. 몇몇 분석가들은 회사의 <a class="ticker" title="분기 재무 결과를 발표한 이후 47.35% 상승했으며, 이에 더해 24회계연도 1년간 좋은 수익 전망을 발표하였습니다. 몇몇 애널리스트들이 &lt;a href=" href="https://www.benzinga.com//node/40284819">목표 주가</a>를 높였다.</li>
<li>베라사이트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>)가 <a href="https://www.benzinga.com//node/40229725" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">예상보다 나은 2분기 재무 실적</a>을 발표한 후 주가는 46.57% 상승했다.</li>
<li>클리어 시큐어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YOU#NYSE">YOU</a>)가 2분기 재무 결과를 보고하고 예상보다 높은 3분기 <a href="https://www.benzinga.com//node/40181525" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">매출 지침</a>을 발표한 후 주가는 38.83% 증가했다.</li>
<li>코어 사이언티픽(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>)의 주가는 코어위브(CoreWeave)가 추가 <a href="https://www.benzinga.com//node/40194866" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">계약 옵션</a>을 행사했다고 발표한 뒤 38.37% 상승했다.</li>
</ol>
다른 뉴스도 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ec%87%bc%ed%94%bc%ed%8c%8c%ec%9d%b4-%eb%b0%8f-%ed%8c%94%eb%9e%80%ed%8b%b0%ec%96%b4%eb%8a%94-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ea%b3%a0-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%97%ac%ec%a4%80-10/" target="_blank" rel="noopener">쇼피파이 및 팔란티어는 지난주 최고 성과를 보여준 10개 대형주 중 일부 (8월 4일-8월 10일)</a></li>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ec%9b%8c%eb%84%88-%eb%b8%8c%eb%9d%bc%eb%8d%94%ec%8a%a4-%eb%b0%8f-%eb%a7%a5%ec%bc%80%ec%8a%a8%ec%9d%80-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ec%95%85%ec%9d%98-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4/" target="_blank" rel="noopener">워너 브라더스 및 맥케슨은 지난주 최악의 성과를 보인 10개 대형주 중 일부 (8월 4일-8월 10일)</a></li>
</ul>
사진 제공: Lumen
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

월요일에 캐시 우드가 주도하는 아크 인베스트(Ark Invest)는 로빈후드 마켓(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>)의 지분을 줄이는 중요한 조치를 취했다. 이 결정은 시장 변동 기간 중에 이루어졌으며 이 투자 회사가 자체 포트폴리오를 조정하는 최근 추세를 따랐다.
로빈후드(HOOD) 매매:
로빈후드에서 포지션을 축소하기로 한 아크 인베스트의 결정은 세 가지 ETF를 통해 실행되었다. ARK Fintech Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKF#NYSE">ARKF</a>)는 31,827주를 매각했고, ARK Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)와 ARK Next Generation Internet ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>)는 각각 215,675주와 76,299주를 매각했다. 월요일 로빈후드의 종가 23.42달러를 기준으로 판매된 주식의 총 가치는 약 760만 달러이다.
로빈후드 주식의 변동성은 <a href="https://www.benzinga.com/news/24/06/39234943/whats-going-on-with-robinhood-stock" target="_blank" rel="noopener">밈 주식 열기가 부활</a>하는 가운데 발생했다. 최근 로빈후드의 CEO 블래디미어 테네브는 게임스탑에 투자한 것으로 유명한 로어링 키티(Roaring Kitty)이라고도 알려진 키스 길(Keith Gill)의 예정된 라이브 스트리밍으로 인한 트래픽 유입을 회사가 처리할 준비가 되었다고 발표했다. 이 회사는 또한 최근 <a href="https://www.benzinga.com/news/24/05/39047461/robinhood-markets-stock-jumps-on-1b-buyback-whats-going-on">10억 달러 규모의 자사주 매입</a>을 발표했는데, 이는 주가 상승 추세에 기여했다.
특히 비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)과 이더리움(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) 등 주요 코인들이 적자로 거래되면서 <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39262872/bitcoin-ethereum-dogecoin-remain-choppy-analyst-forecasts-2x-10x-increase-for-king-crypto-" target="_blank" rel="noopener">고르지 못한 암호화폐 시장</a>을 배경으로 거래가 성사됐다.
다른 중요한 거래:
<ul>
<li>이그젝트 사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>): ARKG 및 ARKK를 통해 주식 매도.</li>
<li>아크투러스 테라퓨틱스 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>): ARKG를 통해 주식 매입.</li>
<li>텔라닥 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>): ARKG를 통해 주식 매도.</li>
<li>인텔리아 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>): ARKG 및 ARKK를 통해 주식 매입.</li>
<li>버브 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>): ARKG 및 ARKK를 통해 주식 매도. 베라사이트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>): ARKG 및 ARKK를 통해 5,804주 매입.</li>
</ul>
다음 읽어보기: <a href="https://www.benzinga.com/markets/equities/24/06/39246807/investor-naval-ravikant-threatens-to-sell-all-tesla-holdings-if-ceo-musks-pay-plan-is-rejected-b?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">CEO 일자리 대안에 대한 투자자의 협상</a>
이 이야기는 <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>의 편집을 거쳐 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>에 의해 제작되었습니다.

$BTC

$ETH

ARCT

ARKF

ARKW

EXAS

HOOD

TDOC

VERV

아크 인베스트가 게임스톱 관련 뉴스와 비트코인 변동성 속에서 로빈후드 주식 $7.6백만 매각

Comments

Veracyte

뉴스

에 대한 최신 뉴스 Veracyte (NASDAQ:VCYT) 주식

화요일, 1월 14, 2025

수요일, 11월 27, 2024

일요일, 8월 11, 2024

화요일, 6월 11, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌